首页|C-TIRADS联合超声造影评估桥本甲状腺炎4类结节

C-TIRADS联合超声造影评估桥本甲状腺炎4类结节

扫码查看
目的 评估甲状腺结节超声恶性危险分层中国指南(Chinese-thyroid imaging reporting and data system,C-TIRADS)联合超声造影(contrast-enhanced ultrasound,CEUS)评估桥本甲状腺炎 4 类结节.方法 回顾性分析 2022 年 6 月至12 月于益阳市中心医院就诊的 79 例桥本甲状腺炎患者的 120 个C-TIRADS 4 类甲状腺结节资料.CEUS检查时如结节表现可疑的 1 种或多种良/恶性特征,均采取降/升一级的处理,以最终手术病理结果为金标准.绘制受试者操作特征曲线(receiver operating characteristic curve,ROC曲线),比较诊断效能.结果 CEUS后再次分级的C-TIRADS诊断甲状腺结节良恶性的敏感度、特异性和准确性分别为 93.0%、87.8%和 90.8%(P<0.05).ROC 曲线下面积分别为 0.811 和0.904(P<0.05).结论 C-TIRADS联合CEUS评估桥本甲状腺炎 4 类结节具有更好的诊断效能.
C-TIRADS combined with contrast-enhanced ultrasound for evaluation of category 4 nodules in Hashimoto's thyroiditis
Objective Evaluation of Chinese-thyroid imaging reporting and data system(C-TIRADS)combined with contrast-enhanced ultrasound(CEUS)for the assessment of category 4 nodules in the setting of Hashimoto's thyroiditis.Methods Retrospective analysis of 120 C-TIRADS category 4 thyroid nodules from 79 patients with confirmed Hashimoto's thyroiditis who attended the Yiyang Central Hospital from June to December 2022.Thyroid nodules exhibiting one or more benign or malignant features that were suspicious on CEUS were treated as downgraded or upgraded one level.Using the final surgical pathology results as the gold standard,working characteristic(ROC)curves of subjects based on C-TIRADS grading before and after CEUS adjustment were plotted to compare diagnostic efficacy.Results The sensitivity,specificity,and accuracy of the CEUS-adjusted C-TIRADS were 93.0%,87.8%and 90.8%,respectively(P<0.05).The area under the ROC curve was 0.811 and 0.904,respectively(P<0.05).Conclusion C-TIRADS combined with CEUS has better diagnostic efficacy in evaluating category 4 nodules in Hashimoto's thyroiditis.

Contrast-enhanced ultrasoundHashimoto's thyroiditisThyroid nodulesImage reporting and data systems

陈思凡、陈锋、唐小芳、陈周、杨柯柯、江芳强

展开 >

湖南中医药大学附属益阳中心医院 益阳市中心医院超声科,湖南益阳 413000

超声造影 桥本甲状腺炎 甲状腺结节 影像报告与数据系统

益阳市科技计划项目

益财教指[2021]133号

2024

中国现代医生
中国医学科学院

中国现代医生

影响因子:1.571
ISSN:1673-9701
年,卷(期):2024.62(3)
  • 1
  • 7